<DOC>
	<DOCNO>NCT02178670</DOCNO>
	<brief_summary>Most study cancer stem cell ( CSC ) involve inoculation cell human tumor immunosuppressed mouse , prevent assessment immunologic interaction effect CSCs . In study , investigator examine vaccination effect produce CSC-enriched population histologically distinct murine tumor inoculation different syngeneic immunocompetent host . Enriched CSCs immunogenic effective antigen source unselected tumor cell induce protective antitumor immunity.Immune sera CSC-vaccinated host contain high level IgG bound CSCs , result CSC lysis presence complement.CTLs generate peripheral blood mononuclear cell splenocytes harvest CSC-vaccinated host capable kill CSCs vitro . Mechanistic investigation establish CSC-primed antibody T cell capable selective target CSCs confer antitumor immunity .</brief_summary>
	<brief_title>Safety Effectivity Immunotherapy Treat Ovarian Cancer With Cancer Stem Cells Vaccine</brief_title>
	<detailed_description>To assess feasibility generate CSC-loaded DC vaccine clinical use , investigator harvest peripheral blood tumor specimen patient ovarian Cancer . The investigator purify T , B cell generate DCs PBMCs ovarian cancer patient.On hand , investigator isolate ALDHhigh ALDHlow tumor cell tumor specimen ovarian cancer patient use similar protocol investigator report . Aim 1 : To demonstrate , vitro , relative cellular anti-ovarian cancer CSC immunity induce ovarian cancer CSC-DC prim cytotoxic T cell . Aim 2 : To determine , vitro , specific bind lysis ovarian cancer CSCs antibody produce purified B cell PBMCs stimulate ovarian cancer CSC-DC .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients epithelial ovarian cancer FIGO ( Fédération Internationale de Gynécologie et d'Obstétrique ) stage III remission treatment surgery ( hysterectomy ovariectomy ) first primary chemotherapy ( standard treatment e.g . 69x Carboplatin/Taxane ) 1 . Age &gt; 18 ≤ 75 year 2 . Histological confirm FIGO stage III ovarian epithelial cancer 3 . Stable disease screen visit : negative CT CA125 within normal range 4 . Karnofsky status ≥ 70 % and/or ECOG ( Eastern Cooperative Oncology Group ) performance status 02 5 . Life expectancy ≥ 6 month 6 . Adequate hematological function ( WBC ( white blood cell ) ≥ 3000/µl , hemoglobin ≥ 10.0 g/dL , platelet &gt; 100,000/µl ) 7 . Adequate renal hepatic function ( serum creatinine ≤ 2.0 mg/dL , bilirubin total &lt; 2 mg/dL , PT ( INR ) ≤ 1.5x institutional upper limit normal ) 8 . Signed date informed consent start studyspecific procedure 9 . Body weight &gt; 50 kg 1 . Surgery , radiation therapy chemotherapy within eight week prior leukapheresis 2 . Other biological therapy ( Interferons , TNF ( Tumor necrosis factor ) , Interleukins , mABs ( Monoclonal antibody ) , biological response modifier ) within eight week prior undergo leukapheresis 3 . History presence systemic autoimmune disease ( , restrict , inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma multiple sclerosis ) 4 . Participation clinical trial treatment investigational drug within four week prior enrollment 5 . Serious intercurrent chronic acute illness severe asthma COPD ( Chronic Obstructive Pulmonary Disease ) , cardiac ( NYHA ( New York Heart Association ) class III IV ) hepatic disease , illness consider constitute unwarranted high risk investigational drug treatment 6 . History another malignancy within five year prior study enrollment , except curatively treat nonmelanotic skin cancer cervical cancer situ 7 . Presence active acute chronic infection , include syphilis , HIV viral hepatitis B and/or C 8 . Current treatment corticosteroid ( except local ) immunosuppressive agent azathioprine cyclosporine A excluded basis potential immune suppression . Any systemic steroid therapy must discontinue six week prior undergo leukapheresis 9 . Patients undergone organ transplantation 10 . Legally incapacitated person and/or circumstance , make difficult subject understand nature , mean consequence clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>